晚期消化道恶性肿瘤中医优势人群特征及诊疗路径研究

杨宇飞

doi:10.3969/j.issn.1006-2157.2022.05.004

您当前的位置：

首页 >

文章列表页 >

晚期消化道恶性肿瘤中医优势人群特征及诊疗路径研究

“中医肿瘤学”专题 | 更新时间：2022-06-02

- 晚期消化道恶性肿瘤中医优势人群特征及诊疗路径研究
- Study on the characteristics of the traditional Chinese medicine dominant population and the optimal dynamic intervention strategy in advanced digestive tract cancers
- 北京中医药大学学报 2022年45卷第5期页码：433-437
- 作者机构：
  
  中国中医科学院西苑医院肿瘤科　北京　100091
- 作者简介：
  
  Prof. YANG Yufei, Ph.D., Chief Physician, Doctoral Supervisor. Xiyuan Hospital, China Academy of Chinese Medical Sciences, No.1, Xiyuan Playground Road, Haidian District, Beijing 100091. E-mail: yyf93@vip.sina.com
- 基金信息：
  
  国家中医药管理局2019年重大疑难疾病中西医临床协作试点项目(070030003);北京市卫生健康委员会2022首都卫生发展科研专项(2022-1-4171);国家中医药管理局中医药传承与创新“百千万”人才工程——岐黄学者(020450004)
- DOI：10.3969/j.issn.1006-2157.2022.05.004
  中图分类号： R273
- 收稿：2022-01-05，
  
  纸质出版：2022-05-30
- 稿件说明：
移动端阅览
杨宇飞. 晚期消化道恶性肿瘤中医优势人群特征及诊疗路径研究[J]. 北京中医药大学学报, 2022,45(5):433-437.

Yufei YANG. Study on the characteristics of the traditional Chinese medicine dominant population and the optimal dynamic intervention strategy in advanced digestive tract cancers[J]. Journal of Beijing University of Traditional Chinese Medicine, 2022, 45(5): 433-437.
杨宇飞. 晚期消化道恶性肿瘤中医优势人群特征及诊疗路径研究[J]. 北京中医药大学学报, 2022,45(5):433-437. DOI： 10.3969/j.issn.1006-2157.2022.05.004.

Yufei YANG. Study on the characteristics of the traditional Chinese medicine dominant population and the optimal dynamic intervention strategy in advanced digestive tract cancers[J]. Journal of Beijing University of Traditional Chinese Medicine, 2022, 45(5): 433-437. DOI： 10.3969/j.issn.1006-2157.2022.05.004.

摘要

近年来，晚期消化道肿瘤西医治疗飞速发展，但其治疗仍存在生存期短、毒副反应大、患者生活质量差等短板。中医治疗强调整体观念、辨证论治，重视患者治疗后的满意度和生活质量改善指标，在改善肿瘤患者的临床症状、提高生存质量、延长生存期及减轻放射治疗、化学药物治疗的毒副反应方面独具特色。近年来笔者团队与北京中医药大学东直门医院、中国医学科学院肿瘤医院和人民大学统计学院合作，在晚期消化道恶性肿瘤中医优势人群特征及诊疗路径等方面进行了一系列的探索与实践，深度挖掘中医药治疗肿瘤的潜力和优势，从而指导临床用药及临床研究，探索出适合中国人的晚期消化道肿瘤的中西医结合诊疗之路。

Abstract

In recent years

the Western medicine treatment of advanced digestive tract cancers has developed rapidly

but it still has shortcomings such as a short survival time

high toxicity

and poor quality of life. Traditional Chinese medicine emphasizes holistic concepts

syndrome differentiation

and treatment

as well as patient satisfaction and quality of life. It is unique in improving the life quality of patients

prolonging their survival time

and reducing the side effects of radiotherapy and chemotherapy. In recent years

this team has cooperated with the Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine

the Cancer Hospital of the Chinese Academy of Medical Sciences

and the School of Statistics of Renmin University to conduct a series of explorations into the characteristics of advanced digestive tract cancers in traditional Chinese medicine and the path of diagnosis and treatment. The potential and advantages of traditional Chinese medicine for the treatment of tumors will guide clinical medication and clinical research and in integrating traditional Chinese and Western medicine for the diagnosis and treatment of advanced digestive tract tumors in a manner suitable for the Chinese people.

关键词

Keywords

references

SUNG H , FERLAY J , SIEGEL RL , et al . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin , 2021 ， 71 ( 3 )： 209 － 249 .

SIEGEL RL , MILLER KD , FUCHS HE , et al . Cancer Statistics, 2021 [J]. CA Cancer J Clin , 2021 ， 71 ( 1 )： 7 － 33 .

CHENG L , ENG C , NIEMAN LZ , et al . Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005 [J]. Am J Clin Oncol , 2011 ， 34 ( 6 )： 573 － 580 .

SHAO C , ZUO Q , LIN J , et al . Effect of Chinese Herbal Medicine on the Survival of Colorectal Cancer Patients with Liver-Limited Metastases: A Retrospective Cohort Study, 2008 to 2017 [J/OL]. Integr Cancer Ther , 2019 ， 18 : 1534735419883687 [ 2021－12－27 ]. https：//www.ncbi.nlm.nih.gov/pmc/articles/PMC6820185/ https：//www.ncbi.nlm.nih.gov/pmc/articles/PMC6820185/ .

ENZINGER PC , ILSON DH , KELSEN DP . Chemotherapy in esophageal cancer [J]. Semin Oncol , 1999 ， 26 ( 5 Suppl 15 )： 12 － 20 .

LAGERGREN J , SMYTH E , CUNNINGHAM D , et al . Oesophageal cancer [J]. Lancet , 2017 ， 390 ( 10110 )： 2383 － 2396 .

DEKKER E , TANIS PJ , VLEUGELS J , et al . Colorectal cancer [J]. Lancet , 2019 ， 394 ( 10207 )： 1467 － 1480 .

SHITARA K , VAN CUTSEM E , BANG YJ , et al . Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients with First-line, Advanced Gastric Cancer: The KEYNOTE－062 Phase 3 Randomized Clinical Trial [J]. JAMA Oncol , 2020 ， 6 ( 10 )： 1571 － 1580 .

BOKU N , RYU MH , KATO K , et al . Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION－4) [J]. Ann Oncol , 2019 ， 30 ( 2 )： 250 － 258 .

YEZEFSKI T A , LE D , CHEN L , et al . Comparison of Treatment, Cost, and Survival in Patients with Metastatic Colorectal Cancer in Western Washington, United States, and British Columbia, Canada [J/OL]. JCO Oncol Pract , 2020 ， 16 ( 5 ): e425 － e432 [ 2021－12－27 ]. https：//ascopubs.org/doi/10.1200/JOP.19.00719 https：//ascopubs.org/doi/10.1200/JOP.19.00719 .

LI J , QIN S , XU RH , et al . Effect of Fruquintinib vs Placebo on Overall Survival in Patients with Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial [J]. JAMA , 2018 ， 319 ( 24 )： 2486 － 2496 .

LI J , QIN S , XU R , et al . Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet Oncol , 2015 ， 16 ( 6 )： 619 － 629 .

VAN CUTSEM E , CERVANTES A , NORDLINGER B , et al . Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J/OL]. Ann Oncol , 2014 ， 25 ( Suppl 3 ): iii1 - iii9 [ 2021－12－27 ]. https：//www.annalsofoncology.org/article/S0923－7534(19)34091－8/fulltext https：//www.annalsofoncology.org/article/S0923－7534(19)34091－8/fulltext .

JASON B . AI in the ER: What is Watson and What Does it Mean for Medical Librarianship? [J]. Journal of Hospital Librarianship , 2011 ， 11 ( 3 ): 289 － 293 .

COLLINS FS , VARMUS H . A new initiative on precision medicine [J]. N Engl J Med , 2015 ， 372 ( 9 )： 793 － 795 .

国务院办公厅．国务院办公厅关于印发全国医疗卫生服务体系规划纲要(2015－2020年)的通知 [J]. 中华人民共和国国务院公报， 2015 ( 10 )： 25 － 39 .

孙凌云，张达，郝洁，等 . 晚期结直肠癌患者中医证型、中医体质与生存结局相关性分析 [J]. 中国中西医结合杂志， 2017 ， 37 ( 9 )： 1059 － 1062 .

徐钰莹 . 真实世界68例晚期结直肠癌中医优势人群特征与基因突变动态趋势分析 [D]. 北京：北京中医药大学， 2018 .

徐钰莹，孙凌云，张长，等 . 晚期结直肠癌中医受益人群特征分析 [J]. 中国中西医结合杂志， 2019 ， 39 ( 7 )： 804 － 809 .

徐钰莹，张文丽，杨宇飞，等 . 晚期结直肠癌中医药干预治疗疗效预测模型的建立与应用 [J]. 世界科学技术—中医药现代化， 2019 ， 21 ( 7 )： 1518 － 1524 .

吴朝旭，纪薇，王寅，等 . 37例接受中医治疗的晚期胃癌死亡患者临床特征分析 [J]. 北京中医药， 2019 ， 38 ( 11 )： 1144 － 1147 .

陈佳阳，杨宇飞，易丹辉，等 . 中医治疗晚期食道癌分析及预后判别 [J]. 基础医学与临床， 2020 ， 40 ( 2 )： 182 － 186 .

NERO C , VIZZIELLI G , LORUSSO D , et al . Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine [J/OL]. J Exp Clin Cancer Res , 2021 ， 40 ( 1 )： 116 [ 2021－12－27 ]. https：//jeccr.biomedcentral.com/articles/10.1186/s13046－021－01917－7 https：//jeccr.biomedcentral.com/articles/10.1186/s13046－021－01917－7 .

NEW NRCU , DISEASE TO . Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease [M]. Washington (DC) : National Academies Press (US) , 2011 ： 32 .

徐钰莹 . 晚期结直肠癌中医优势人群判别模型的建立与动态治疗策略的探索 [D]. 北京：北京中医药大学， 2021 .

查看原文

浏览量

152

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

全球结直肠癌与2型糖尿病共病模式、危险因素及未来预测分析

证候特征诠释视角下证候标准化的思路探讨与实践

不同代谢-体重分型下冠心病心绞痛患者的中医证候及体质特点分析

“离经之精”视角下肾性蛋白尿中医病机解析与辨治思路构建

从“三焦-膜原-肾络”探析IgA肾病的病机与防治